Aequitron Medical acquires central nervous systems (CNS) sleep diagnostic range:
This article was originally published in Clinica
Electronic respiratory product manufacturer Aequitron Medical is to acquire CNS' sleep diagnostic business which has annual revenues of $7 million. The combined $6 million cash and debt transaction gives Aequitron rights to all CNS' sleep disorder diagnostic products as well as a product in development. It also gains distribution rights to CNS' Breathe Right nasal strips to professional healthcare markets. Production and staffing for the CNS products will move to Aequitron Medical's headquarters in Plymouth, Minnesota. CNS chairman and CEO Daniel Cohen says the company intends to concentrate on developing its core business - the Breathe Right product line.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.